ArticleJournal of the American Society of Nephrology : JASN2017
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05916781 (Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus), which is not on this map. Cited by 56 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial
Who cites it
56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Efficacy and safety of biologics, multitarget therapy, and standard therapy for lupus nephritis: a systematic review and network meta-analysis.Renal failure · 2024Pooled it
- Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Pooled it
- Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis.Clinical rheumatology · 2019Pooled it
- A prospective study to compare the efficacy and safety of glucocorticoid-free maintenance therapy versus low-dose glucocorticoid maintenance therapy for lupus nephritis-a pilot, single-center, randomized controlled study.Clinical rheumatology · 2026Trial
- Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide.Clinics (Sao Paulo, Brazil) · 2020Trial
- Efficacy and safety of belimumab in lupus nephritis: a real-world retrospective observational study stratified by treatment phase and age.Clinical rheumatology · 2026Observational
- The Evolution of Lupus Nephritis Therapy from the 1960s to the Present.Bioengineering (Basel, Switzerland) · 2026Review
- Can Phagocytosis, Neutrophil Extracellular Traps, and IFN-α Production in Systemic Lupus Erythematosus Be Simultaneously Modulated? A Pharmacological Perspective.International journal of molecular sciences · 2026Review
- Expanding therapeutic horizons of calcineurin inhibitors in lupus nephritis: from tacrolimus to next-generation agents.The Korean journal of internal medicine · 2025Article
- Real-world clinical response and efficacy of tacrolimus-based maintenance therapy for Korean patients with lupus nephritis.The Korean journal of internal medicine · 2025Article
- 2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus.Rheumatology and immunology research · 2025Article
- Induction therapy for class I/II lupus nephritis with glucocorticoid monotherapy associates with higher relapse and poorer kidney outcomes.Clinical kidney journal · 2025Article
- Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents.Rheumatology and therapy · 2025Review
- Advances in Multitarget Therapeutic Approaches for Immune-Mediated Glomerular Diseases.Life (Basel, Switzerland) · 2025Article
- New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis.Journal of clinical medicine · 2025Review
- Efficacy of belimumab on extra-renal lupus in patients with lupus nephritis and end-stage renal disease.Frontiers in medicine · 2025Article
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients.BMC rheumatology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous studies showed that multitarget therapy is superior in efficacy to intravenous cyclophosphamide as an induction treatment for lupus nephritis in Asian populations. We conducted an open label, multicenter study for 18 months as an extension of the prior induction therapy trial in 19 renal centers in China to assess the efficacy and safety of multitarget maintenance therapy in patients who had responded at 24 weeks during the induction phase. Patients who had undergone multitarget induction therapy continued to receive multitarget therapy (tacrolimus, 2-3 mg/d; mycophenolate mofetil, 0.50-0.75 g/d; prednisone, 10 mg/d), and patients who had received intravenous cyclophosphamide induction treatment received azathioprine (2 mg/kg per day) plus prednisone (10 mg/d). We assessed the renal relapse rate during maintenance therapy as the primary outcome. We recruited 116 patients in the multitarget group and 90 patients in the azathioprine group. The multitarget and azathioprine groups had similar cumulative renal relapse rates (5.47% versus 7.62%, respectively; adjusted hazard ratio, 0.82; 95% confidence interval, 0.25 to 2.67;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.